RATIONALE: Mycoplasma pneumoniae was recently discovered to produce an ADP-ribosylating and vacuolating cytotoxin, designated CARDS toxin, which is hypothesized to be a primary pathogenic mechanism responsible for M. pneumoniae-induced pulmonary inflammation. It is unknown if cytotoxin production varies with M. pneumoniae strain or if variation in cytotoxin production affects pulmonary disease severity. OBJECTIVES: To examine the production of CARDS toxin by various strains of M. pneumoniae and compare the disease manifestations elicited by these strains in an experimental model of M. pneumoniae respiratory infection. METHODS: BALB/c mice were inoculated once intranasally with SP4 broth (negative control) or three different M. pneumoniae strains: M129-B7, M129-B9, or S1. Mice were assessed at 1, 2, 4, 7, 10, and 14 days after inoculation. Outcome variables included comparisons among M. pneumoniae strains relative to bronchoalveolar lavage (BAL) M. pneumoniae quantitative culture, CARDS toxin-based PCR, and CARDS toxin protein determinations, as well as cytokine and chemokine concentrations. Graded lung histopathologic score (HPS) was also assessed. MEASUREMENTS AND MAIN RESULTS: CARDS toxin concentrations were significantly increased in mice inoculated with strain S1 compared with mice inoculated with M129-B7 or M129-B9 strains. Quantitative M. pneumoniae culture and polymerase chain reaction were also significantly greater in mice infected with S1 strain compared with the other two strains, as were lung HPS and concentrations of IFN-γ, IL-12, IL-1α, macrophage inflammatory protein-1α, and keratinocyte-derived chemokine. In addition, a significant positive correlation was found between CARDS toxin concentration and lung HPS. CONCLUSIONS: CARDS toxin concentrations in BAL are directly linked to the ability of specific M. pneumoniae strains to colonize, replicate, and persist, and elicit lung histopathology. This variation among strains may predict the range in severity of pulmonary disease observed among patients.
RATIONALE: Mycoplasma pneumoniae was recently discovered to produce an ADP-ribosylating and vacuolating cytotoxin, designated CARDS toxin, which is hypothesized to be a primary pathogenic mechanism responsible for M. pneumoniae-induced pulmonary inflammation. It is unknown if cytotoxin production varies with M. pneumoniae strain or if variation in cytotoxin production affects pulmonary disease severity. OBJECTIVES: To examine the production of CARDS toxin by various strains of M. pneumoniae and compare the disease manifestations elicited by these strains in an experimental model of M. pneumoniae respiratory infection. METHODS: BALB/c mice were inoculated once intranasally with SP4 broth (negative control) or three different M. pneumoniae strains: M129-B7, M129-B9, or S1. Mice were assessed at 1, 2, 4, 7, 10, and 14 days after inoculation. Outcome variables included comparisons among M. pneumoniae strains relative to bronchoalveolar lavage (BAL) M. pneumoniae quantitative culture, CARDS toxin-based PCR, and CARDS toxin protein determinations, as well as cytokine and chemokine concentrations. Graded lung histopathologic score (HPS) was also assessed. MEASUREMENTS AND MAIN RESULTS: CARDS toxin concentrations were significantly increased in mice inoculated with strain S1 compared with mice inoculated with M129-B7 or M129-B9 strains. Quantitative M. pneumoniae culture and polymerase chain reaction were also significantly greater in mice infected with S1 strain compared with the other two strains, as were lung HPS and concentrations of IFN-γ, IL-12, IL-1α, macrophage inflammatory protein-1α, and keratinocyte-derived chemokine. In addition, a significant positive correlation was found between CARDS toxin concentration and lung HPS. CONCLUSIONS: CARDS toxin concentrations in BAL are directly linked to the ability of specific M. pneumoniae strains to colonize, replicate, and persist, and elicit lung histopathology. This variation among strains may predict the range in severity of pulmonary disease observed among patients.
Authors: Hong Wei Chu; Joyce M Honour; Catherine A Rawlinson; Ronald J Harbeck; Richard J Martin Journal: Infect Immun Date: 2003-03 Impact factor: 3.441
Authors: S Esposito; R Cavagna; S Bosis; R Droghetti; N Faelli; N Principi Journal: Eur J Clin Microbiol Infect Dis Date: 2002-08-08 Impact factor: 3.267
Authors: T R Kannan; R D Hardy; J J Coalson; D C Cavuoti; J D Siegel; M Cagle; O Musatovova; C Herrera; J B Baseman Journal: Clin Infect Dis Date: 2011-11-03 Impact factor: 9.079
Authors: Jorge L Medina; Jacqueline J Coalson; Edward G Brooks; Vicki T Winter; Adriana Chaparro; Molly F R Principe; Thirumalai R Kannan; Joel B Baseman; Peter H Dube Journal: Am J Respir Cell Mol Biol Date: 2012-01-26 Impact factor: 6.914
Authors: Jay Peters; Harjinder Singh; Edward G Brooks; Joseph Diaz; Thirumalai R Kannan; Jacqueline J Coalson; Janet G Baseman; Marianna Cagle; Joel B Baseman Journal: Chest Date: 2011-05-26 Impact factor: 9.410
Authors: Sowmya Balasubramanian; Lavanya Pandranki; Suzanna Maupin; Kumaraguruparan Ramasamy; Alexander B Taylor; Peter John Hart; Joel B Baseman; Thirumalai R Kannan Journal: Cell Microbiol Date: 2019-05-09 Impact factor: 3.715
Authors: Jesus A Segovia; Te-Hung Chang; Vicki T Winter; Jacqueline J Coalson; Marianna P Cagle; Lavanya Pandranki; Santanu Bose; Joel B Baseman; Thirumalai R Kannan Journal: Infect Immun Date: 2017-12-19 Impact factor: 3.441
Authors: Pamela R Wood; Vanessa L Hill; Margaret L Burks; Jay I Peters; Harjinder Singh; Thirumalai R Kannan; Shruthi Vale; Marianna P Cagle; Molly F R Principe; Joel B Baseman; Edward G Brooks Journal: Ann Allergy Asthma Immunol Date: 2013-02-23 Impact factor: 6.347